About Us

About Us

Catenion is a management consulting firm devoted to helping pharmaceutical and medical products companies create more innovative and effective strategies and organizations.

We draw on our deep understanding of industry trends and company dynamics to help our clients develop actionable competitive strategies. We also address the cultural impediments to pharmaceutical innovation by helping clients create the organizational climates that foster creativity and medical breakthroughs. At the same time we also greatly improve how our clients assess the value and risk of their project and product portfolios and how they allocate resources.

We work with board directors, CEOs, business unit general managers, heads of R&D, finance, strategy, portfolio management, business development and other executives who want to improve the performance of the organization. We are able to do so because of three differentiators:

Science-Driven Strategy

We focus on science-driven strategy: we answer key questions through comprehensive multidimensional assessments conducted by our team of life science PhDs.

Experience & Relationships

We have two decades of experience and relationships globally across the biopharmaceutical industry.

Data Science

We integrate Data Science in our analyses with a team of bioinformaticians, computational biologists and data engineers.

We are equally passionate about helping our clients boost innovation and thus contributing to medical advances. We are constantly seeking entrepreneurial opportunities related to our core capabilities and are willing to go at risk.

Our Values

A number of principles have shaped, and will continue to shape, our firm:

As a result, we continually perfect and re-invent our approaches and analytical methods, always go the extra mile, and are much better at delivering our services than at selling ourselves.
Catenion partners and consultants are here because they love the work they do — not to build a CV and use their experience as a stepping stone on the path to professional glory.

Meet the Team

Code of Ethics

At Catenion, integrity, ethics and transparency are very important. Therefore, we are proud to share our Code of Ethics with our clients, providers and team.
Catenion Arno Heuermann 2

Arno Heuermann

Arno Heuermann is a founding Partner of Catenion who lives in Berlin, Germany. Arno has ten years of experience as CEO and COO. He has managed companies in Germany, France and Luxemburg.

While working on his degrees, Arno founded a technical engineering office in 1994. He continued to follow the entrepreneurial path in 1998 by founding Biopsytec GmbH, a DNA diagnostics company focused on agriculture, heading the company for more than five years as Managing Director.

In 1999, he co–founded Epigenomics AG, a public biotech company focused on DNA methylation, later remaining as an advisor and member of the firm’s Supervisory Board.

In August 2000, Arno orchestrated the founding and financing of Biopsytec Holding AG, thus merging Genious SA and the QTL AG and Biopsytec GmbH. He managed Biopsytec Holding AG for the next three years before helping launch Catenion in 2003. Since that time, he has been Catenion’s chief operating officer.

Arno holds a diploma degree in process engineering from the Technical University of Applied Sciences in Berlin. In addition, Arno attended the Berlin business school for Industrial Engineering and Management.

He is experienced in the diverse practices of patent management and has made numerous successful inventions.

Arno Heuermann is married and has two children. He is a lover of classical music, country life and horseback riding.

Catenion Matthias Krings

Dr. Matthias Krings

Matthias Krings is a founding Partner of Catenion.

He has worked for international pharma, biotech and medtech organizations on a variety of topics. Matthias works with clients on developing corporate and R&D strategies, identifying new areas of opportunity, tailoring asset and company searches for BD&L and M&A, maximizing the value of existing assets through therapeutic expansion, and prioritizing R&D portfolios. Matthias is also responsible for the creation and delivery of bespoke client education programs in the Catenion Academy.

Before co-founding Catenion in 2003, Matthias was a consultant at Mercer Management Consulting (now Oliver Wyman) and later joined a strategy consulting boutique, Theron.

Matthias holds a diploma and a doctorate degree in Biology from the Ludwig-Maximilians University in Munich. His PhD work was supported by a scholarship from the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine. Matthias made significant scientific contributions to the field of human evolution, published in Krings et al., Cell 1997: Neandertal DNA Sequences and the Origin of Modern Humans. His PhD supervisor Svante Pääbo was awarded the Nobel Prize in Physiology or Medicine in 2022 “for his discoveries concerning the genomes of extinct hominins and human evolution”.

Matthias lives in Munich. He enjoys cooking, gardening, water sports and traveling.

Catenion Christian Elze

Christian Elze

Christian Elze is a founding partner of Catenion and has been developing the company’s business in Japan since 2008. He holds a BSc from the London School of Economics and an MBA from Columbia University.

As of January 2024, Christian is moving to a role of Senior Partner Emeritus; while continuing to look after selected clients and projects, he is reducing his time spent with the company; he has accepted positions as a member of the Scientific Advisory Board of Recordati in Milan and a Board Observer of Pangea Biomed in Tel Aviv.

Christian is working with companies, universities and governments in the field of biomedical innovation. In his work, Christian is focusing on how emerging technologies and translational research are re-shaping the respective roles of funding agencies, investors, biopharma companies and academia in the research and development of new drugs.

Besides his consulting work, Christian frequently speaks about Emerging Technologies, Healthcare Reform, Pricing & Reimbursement,  Biomedical Innovation, as well as Translational Research at industry conferences and universities in Japan, the US and Europe.

Christian is a fluent speaker of English, French, German, Italian, Portuguese, Russian and Spanish and divides his time between London and Alto Paraiso de Goias in Brazil.

Catenion Markus Thunecke compressed

Dr. Markus Thunecke

Markus has written several Catenion Commentaries including “Risk Profiles of Corporate Portfolio Strategies” as well as “Elements of Winning Strategies in R&D”, “Recombinant Innovation Management (RIM) – How to Stimulate Breakthrough Innovation within Large R&D Organisations”, “Recombinant Portfolio Management – Recognising and Enabling Innovation”. He also co–authored “Zero Base R&D” and “The Challenge for Japan’s Pharmaceutical Top Twenty”. All of them are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high-profile issues for the industry.

Markus Thunecke is a founding Senior Partner of Catenion who lives in Berlin, Germany. Markus started his consulting career in 1997 at Mercer Management Consulting before joining a strategy consulting boutique, Theron, and setting up Catenion in 2003.

Markus has helped numerous clients around the globe in the pharmaceutical and medical products industries create competitive advantage. In addition to his work on strategy, Markus specialises in developing leading–edge analytical tools and combining them with organisational development capabilities. Markus is the developer of a number of Catenion’s proprietary tools for portfolio management and risk assessment. In recent engagements, Markus has helped clients develop and realign their R&D strategies, review their discovery and development portfolios, and create organisational models that foster innovation.

Markus is a frequent speaker at conferences on R&D strategy and portfolio management.

He holds a PhD in biochemistry from the University of Heidelberg, where he generated transgenic animal models for Alzheimer’s disease. He also has three years of research experience within the CNS field at Schering AG.